Table 2.
Phase III trials of sunitinib in advanced breast cancer

Progression-free survival was the primary endpoint.
aOne-sided p value.
Abbreviations: CI, confidence interval; HR, hazard ratio; NR, not reached; NS, not significant.
Phase III trials of sunitinib in advanced breast cancer

Progression-free survival was the primary endpoint.
aOne-sided p value.
Abbreviations: CI, confidence interval; HR, hazard ratio; NR, not reached; NS, not significant.